BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27066721)

  • 1. Long-term Outcomes of Limited Vogt-Koyanagi-Harada Syndrome.
    Chew SK; Levy J; Rogers S; Lim LL
    Am J Ophthalmol; 2016 Jul; 167():52-6. PubMed ID: 27066721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vogt-Koyanagi-Harada syndrome in a 4-year-old child.
    Gruich MJ; Evans OB; Storey JM; Bradley ST; Chen CJ
    Pediatr Neurol; 1995 Jul; 13(1):50-1. PubMed ID: 7575849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tomographic features of serous retinal detachment with multilobular dye pooling in acute Vogt-Koyanagi-Harada disease.
    Yamaguchi Y; Otani T; Kishi S
    Am J Ophthalmol; 2007 Aug; 144(2):260-5. PubMed ID: 17533104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
    Nakayama M; Keino H; Watanabe T; Okada AA
    Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RETINAL PIGMENT EPITHELIUM UNDULATIONS IN ACUTE STAGE OF VOGT-KOYANAGI-HARADA DISEASE: Biomarker for Functional Outcomes After High-Dose Steroid Therapy.
    Hashizume K; Imamura Y; Fujiwara T; Machida S; Ishida M; Kurosaka D
    Retina; 2016 Feb; 36(2):415-21. PubMed ID: 26352553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
    Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
    BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolution of subretinal fluid with systemic corticosteroid treatment in acute Vogt-Koyanagi-Harada disease.
    Nazari H; Rao NA
    Br J Ophthalmol; 2012 Nov; 96(11):1410-4. PubMed ID: 22942161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACILLARY LAYER DETACHMENT IN ACUTE VOGT-KOYANAGI-HARADA DISEASE: A Novel Swept-Source Optical Coherence Tomography Analysis.
    Agarwal A; Freund KB; Kumar A; Aggarwal K; Sharma D; Katoch D; Bansal R; Gupta V;
    Retina; 2021 Apr; 41(4):774-783. PubMed ID: 32833410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
    Park UC; Cho IH; Lee EK; Yu HG
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutton fat-like subretinal precipitates associated with Vogt-Koyanagi-Harada disease.
    Hamabata K; Hashizume K; Ishikawa Y; Fujiwara T; Machida S; Kurosaka D
    Ocul Immunol Inflamm; 2010 Jan; 18(1):44-5. PubMed ID: 20128649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome.
    Andrade RE; Muccioli C; Farah ME; Nussenblatt RB; Belfort R
    Am J Ophthalmol; 2004 Mar; 137(3):572-4. PubMed ID: 15013890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease.
    Khalifa Y; Loh AR; Acharya NR
    Ocul Immunol Inflamm; 2009; 17(6):431-3. PubMed ID: 20001265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease.
    Lu S; Taban M
    Digit J Ophthalmol; 2016; 22(2):54-7. PubMed ID: 27582676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical coherence tomography in the acute and chronic phases of Vogt-Koyanagi-Harada disease.
    Parc C; Guenoun JM; Dhote R; Brézin A
    Ocul Immunol Inflamm; 2005; 13(2-3):225-7. PubMed ID: 16019683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated choroidal blood flow velocity during systemic corticosteroid therapy in Vogt-Koyanagi-Harada disease.
    Hirose S; Saito W; Yoshida K; Saito M; Dong Z; Namba K; Satoh H; Ohno S
    Acta Ophthalmol; 2008 Dec; 86(8):902-7. PubMed ID: 19016661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease.
    Lai TY; Chan RP; Chan CK; Lam DS
    Eye (Lond); 2009 Mar; 23(3):543-8. PubMed ID: 18369377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Vogt-Koyanagi-Harada disease in enhanced spectral-domain optical coherence tomography.
    Ishihara K; Hangai M; Kita M; Yoshimura N
    Ophthalmology; 2009 Sep; 116(9):1799-807. PubMed ID: 19643489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vogt-Koyanagi-Harada syndrome (clinical cases)].
    Sorokin EL; Voronina NV; Avramenko SY; Pomytkina NV
    Vestn Oftalmol; 2015; 131(3):90-98. PubMed ID: 26310014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
    Read RW; Yu F; Accorinti M; Bodaghi B; Chee SP; Fardeau C; Goto H; Holland GN; Kawashima H; Kojima E; Lehoang P; Lemaitre C; Okada AA; Pivetti-Pezzi P; Secchi A; See RF; Tabbara KF; Usui M; Rao NA
    Am J Ophthalmol; 2006 Jul; 142(1):119-24. PubMed ID: 16815259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pulse corticosteroid therapy for vogt-koyanagi-harada disease assessed by optical coherence tomography.
    Yamanaka E; Ohguro N; Yamamoto S; Nakagawa Y; Imoto Y; Tano Y
    Am J Ophthalmol; 2002 Sep; 134(3):454-6. PubMed ID: 12208266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.